Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021.
The UK government has signed a €1.4 billion ($1.66 billion) order for up to 190 million doses of a coronavirus vaccine in development at French company Valneva.
The UK has secured 90 million doses of two different COVID-19 vaccines from BioNTech/Pfizer and Valneva, with an option of 40 million doses if they check out in trials.